Select a medication above to begin.
Votrient
pazopanib
Black Box Warnings .
Hepatotoxicity
severe and fatal hepatotoxicity observed in clinical trials; monitor LFTs at baseline, then at weeks 3, 5, 7, 9, then at months 3 and 4, then periodically; monitor more frequently qwk if ALT 3-8x ULN until improvement to Grade 1 or baseline; withhold tx if ALT >8x ULN until improvement to Grade 1 or baseline, may resume at reduced dose w/ qwk monitoring x8wk; permanently D/C tx if bilirubin >2x ULN and ALT >3x ULN
Adult Dosing .
Dosage forms: TAB: 200 mg
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments; D/C >1wk before elective surgery, restart >2wk after major surgery when wound fully healed
renal cell CA, advanced
- [800 mg PO qd]
- Info: give at least 1h before or 2h after meals; do not cut/crush/chew tab
soft tissue sarcoma, advanced
- [800 mg PO qd]
- Info: for pts w/ previously treated dz; give at least 1h before or 2h after meals; do not cut/crush/chew tab
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.6-3x ULN: 200 mg qd; bilirubin >3x ULN: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.